Millions of Americans Could Be Eligible for Covid Vaccine Booster

The Food and Drug Administration would first need to decide whether third doses are safe and effective for Pfizer-BioNTech and Moderna, the two vaccines that were rolled out first and have been most used.,


Continue reading the main story

Supported by

Continue reading the main story

More than five million Americans could be eligible for booster shots of the Covid-19 vaccine by late September under the Biden administration’s plan to combat the Delta variant by giving extra doses eight months after initial vaccinations.

But the plan depends on several crucial steps taking place in the coming weeks. Most important, the Food and Drug Administration would need to decide that third shots are safe and effective for Pfizer-BioNTech and Moderna, the two vaccines that were rolled out first and have been most used.

Pfizer is further along in submitting data to the F.D.A. that it says supports the use of boosters. Moderna and the National Institutes of Health are still studying whether a half-dose or a full dose would work better for a third shot, but they expect results soon. Moderna’s chief executive, Stephane Bancel, has said the firm plans to submit its data to the F.D.A. next month.

Administration officials are to announce the strategy at a White House briefing on Wednesday. Nursing home residents, health care workers and emergency workers would probably be first in line. Other older people would be next, followed by the rest of the general population.

Officials envision giving people the same vaccine they originally received, and using pharmacies as key distribution points.

Administration officials are discouraging people from seeking booster doses on their own, noting that the F.D.A. has yet to rule on their safety and efficacy. Nonetheless, the C.D.C. says that more than a million Americans have already obtained them, apparently by pretending they were unvaccinated. They hope to roll out extra shots in an orderly way so people get a booster shot when it is recommended, not simply based on their own fears.

Dr. Danny Avula, the vaccine coordinator for the state of Virginia, said that his state had thousands of vaccine providers already in place and could most likely manage boosters without much change. “What caused so much of the urgency and frenzy of January through April was the limitations in supply,” he said.

The government has more than 100 million doses stockpiled that could be used for boosters, along with tens of millions more doses that have already been delivered to pharmacies and other locations. Even more supply is scheduled for delivery this fall.

In interviews on Tuesday, hospital officials and doctors were supportive of the push for booster shots.

“I think we’re running out of second chances,” said Dr. Matthew Harris, the medical director of the coronavirus vaccination program at Northwell Health, New York’s largest hospital system. “What keeps me up at night is the inevitability of a variant that is not responsive to the vaccine, so if this is how we stay ahead of it, I fully support it.”

Federal officials envision offering additional shots to recipients of the single dose Johnson & Johnson vaccine, as well as those who got Moderna or Pfizer. But the government only began offering the Johnson & Johnson vaccine in March, and only 14 million people have gotten it. By comparison, 155 million people have been fully vaccinated with either Pfizer or Moderna.

Data from a Johnson & Johnson clinical trial in which participants were given two doses is likely to be submitted to the F.D.A. later this month and will guide the government’s recommendation on that vaccine.

At Wednesday’s briefing, administration officials plan to make the case that a booster strategy is essential even if it must be amended as more data comes in. They are expected to present data showing that vaccine efficacy is declining even though unvaccinated people still make up the vast majority of those who become seriously ill or are hospitalized.

Leave a Reply